Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII?

Kessler, Craig
October 2002
Intensive Care Medicine;Oct2002 Supplement 2, Vol. 28, pS228
Academic Journal
journal article
Recombinant activated factor VII (rFVIIa, 'NovoSeven') is indicated for the treatment of bleeding in patients with haemophilia and inhibitors to factors VIII or IX. However, by virtue of its ability to promote thrombin generation on the platelet surface rFVIIa may also be effective in non-haemophilic bleeding, for example, in patients with thrombocytopenic or oral anticoagulant-induced haemorrhage. Studies in thrombocytopenia indicate that rFVIIa increases the generation of thrombin at the site of injury, leading to the control of bleeding episodes in these conditions. Additionally, preclinical and early clinical evidence has demonstrated the ability of rFVIIa to normalise prothrombin times and international normalised ratios in situations of over-anticoagulation. Although initial observations indicate that rFVIIa may be fast, efficacious, and safe in reversing oral anticoagulant-induced bleeds and those associated with thrombocytopenia, randomised, double-blind, placebo-controlled trials must be conducted to confirm its utility in these and other investigational uses.


Related Articles

  • Updates in the management of severe coagulopathy in trauma patients. Lynn, Mauricio; Jeroukhimov, Igor; Klein, Yoram; Martinowitz, Uri // Intensive Care Medicine;Oct2002 Supplement 2, Vol. 28, pS241 

    Coagulopathy is the major cause of bleeding-related mortality in patients who survive the operating room. Its association with hypothermia and metabolic acidosis is common and constitutes a vicious cycle. Usually, post-traumatic coagulopathy is an early event and may be present during surgery....

  • Ongoing NovoSeven trials. Erhardtsen, Elisabeth // Intensive Care Medicine;Oct2002 Supplement 2, Vol. 28, pS248 

    Recombinant activated factor VII (rFVIIa, 'NovoSeven' was initially developed for the treatment of bleeding in patients with haemophilia and inhibitors, and is currently licensed in most countries worldwide. The mechanism of action suggests that its enhancing effects in haemostasis are limited...

  • Intracerebral hemorrhage: natural history and rationale of ultra-early hemostatic therapy. Mayer, Stephan A. // Intensive Care Medicine;Oct2002 Supplement 2, Vol. 28, pS235 

    Stroke is a major health problem worldwide, causing high morbidity and mortality. Intracerebral hemorrhage (ICH) accounts for 15% of stroke cases in the US and Europe and up to 30% in Asian populations. It is less treatable than other forms of stroke and causes higher morbidity and disability....

  • Coexistence of lupus anticoagulant and acquired haemophilia in a patient with monoclonal gammopathy of unknown significance. Taher, A.; Abiad, R.; Uthman, I. // Lupus;2003, Vol. 12 Issue 11, p854 

    Acquired haemophilia or factor VIII (FVIII) deficiency,caused by FVIII inhibitor antibodies, is avery rare condition that commonly results in severe haemorrhagic complications. We report a case of acquired haemophilia presenting with a left calf nontraumatic haematoma. The patient was also found...

  • THE ANTITHROMBOTIC PROPERTIES OF COUMARIN DRUGS. Hoak, John C.; Connor, William E.; Warner, Emory D.; Carter, John R. // Annals of Internal Medicine;Jan61, Vol. 54 Issue 1, p73 

    Studies the association between clotting factor deficiencies and prolongation of the whole blood silicone clotting time in patients treated with coumarin drugs. Prothrombin time; whole blood clotting times in plain glass and in silicone coated tubes; Correlation between the silicone clotting...

  • In vivo bypass of hemophilia A coagulation defect by Factor XIIa implant. Ton-That, Tung T.; Doron, David; Pollard, Bette S.; Bacher, John; Pollard, Harvey B. // Nature Biotechnology;Mar2000, Vol. 18 Issue 3, p289 

    Hemophilia A and B coagulation defects, which are caused by deficiencies of Factor VIII and Factor IX, respectively, can be bypassed by administration of recombinant Factor VIIa. However, the short half-life of recombinant Factor VIIa in vivo negates its routine clinical use. We report here an...

  • Hemophilia with Factor VIII Inhibitor. Stein, Richard S.; Colman, Robert W. // Annals of Internal Medicine;Jul73, Vol. 79 Issue 1, p84 

    Presents a study which described a case on the elimination of factor VIII inhibitors after a combined treatment with factor VIII of hemophilia. Materials and methods; Results; Discussion.

  • Suppression of Factor IX Antibody in Hemophilia B by Factor IX and Cyclophosphamide. Nilsson, I.M.; Hedner, U.; Bjorlin, G. // Annals of Internal Medicine;Jan73, Vol. 78 Issue 1, p91 

    Focuses on a study which described two patients with severe hemophilia B complicated by inhibitors of factor IX. Plasma inhibition of normal plasma recaldification time; Measurement of factor IX inhibitor; Treatment.

  • KaraciÄŸer hastalıklarında pıhtılaÅŸma-tromboz mekanizmasına neler oluyor? Tiraje Celkan, Tülin // Turkish Pediatrics Archive / Turk Pediatri Arsivi;Jun2013, Vol. 48 Issue 2, p94 

    Children with liver disease present complex and varied acquired coagulation abnormalities. Liver is the place where clotting factors are produced as well as inhibitors of coagulation and fibrinolytic system components. Although 75-85% of patients with liver disease show abnormal laboratory...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics